๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Gait analysis in patients with Parkinson's disease and motor fluctuations: Influence of levodopa and comparison with other measures of motor function

โœ Scribed by John D. O'Sullivan; Catherine M. Said; Louise C. Dillon; Marion Hoffman; Dr. Andrew J. Hughes


Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
727 KB
Volume
13
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

โœฆ Synopsis


Abstract

Although clinical rating scales and simple timed tests of motor function are widely used to assess motor response to therapy, gait analysis may provide an alternative measure of this response. We studied 15 patients with PD complicated by motor fluctuations, first to determine changes in temporal and spatial gait parameters following levodopa, secondly to assess the stability of repeated gait measures and timed tests in โ€œoffโ€ and โ€œonโ€ states, and thirdly to determine the use of gait analysis in the assessment of the dopaminergic response. Gait analysis (velocity, stride length, cadence, and double limb support), clinical rating scales (modified Webster scale and Hoehn and Yahr stage), and timed tests of motor function (hand tapping and standโ€walkโ€sit time) were performed before (โ€œoffโ€) and after (โ€œonโ€) a levodopa challenge. Stride length and gait velocity increased following medication whereas cadence and double limb support did not. Most gait measures and the standโ€walkโ€sit time were stable over three consecutive trials in both โ€œoffโ€ and โ€œonโ€ states. Of the gait measures, only cadence in the โ€œoffโ€ state changed significantly whereas the tapping count improved with repeated trials in both โ€œoffโ€ and โ€œonโ€ states. Changes in stride length, gait velocity, and tapping count following levodopa correlated with changes in clinical rating scales following treatment. Measurement of gait parameters provides a reliable, objective alternative to rating scales and timed tests in assessing the dopaminergic response in patients with PD and motor fluctuations.


๐Ÿ“œ SIMILAR VOLUMES


Study of istradefylline in patients with
โœ Robert A. Hauser; Lisa M. Shulman; Joel M. Trugman; John W. Roberts; Akihisa Mor ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 150 KB ๐Ÿ‘ 1 views

## Abstract The objective of this study was to evaluate the efficacy, safety, and tolerability of istradefylline 20 mg once daily versus placebo as an adjunct to levodopa in subjects with Parkinson's disease (PD) who have motor fluctuations. Istradefylline (KWโ€6002) is an adenosine A~2A~ receptor a

Motor fluctuations during continuous lev
โœ John G. Nutt; Julie H. Carter; Eric S. Lea; William R. Woodward ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 975 KB

## Abstract The cause of motor fluctuations occurring during constantโ€rate levodopa infusions is unknown. We examined whether known pharmacokinetic factors could explain the fluctuations and looked for clues to pharmacodynamic causes. Eleven subjects with stage IIIโ€“V Parkinson's disease (PD) and a

Randomized trial of tolcapone versus per
โœ William Koller; Andrew Lees; Miroslava Doder; Mariese Hely ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 103 KB ๐Ÿ‘ 1 views

## Abstract In this 12โ€week, randomized, openโ€label, blindedโ€rater, parallelโ€group trial, the efficacy, safety, and tolerability of tolcapone and pergolide were compared in parkinsonian patients with a fluctuating response to levodopa. Patients received tolcapone 100 mg three times daily (t.i.d.),

Freezing of gait and executive functions
โœ Marianna Amboni; Autilia Cozzolino; Katia Longo; Marina Picillo; Paolo Barone ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 161 KB ๐Ÿ‘ 1 views

## Abstract Freezing of gait (FOG) is a frequent, disabling symptom of Parkinson's disease (PD). FOG usually lasts a few seconds. It refers to brief paroxysmal events during which a subject is unable to start or continue locomotion. Despite its frequency, FOG pathophysiology is unclear. Because a f

Early treatment benefits of ropinirole p
โœ Bonnie P. Hersh; Nancy L. Earl; Robert A. Hauser; Mark Stacy ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 488 KB ๐Ÿ‘ 1 views

A correct balance between endocannabinoid and dopamine-dependent systems is believed to underlie physiological motor control. We measured the levels of the endocannabinoid anandamide in the cerebrospinal fluid of Parkinson's disease (PD) patients. Subjects were divided into three groups: newly diagn